Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: QLT Inc. Clear all

Conditions: LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Interventions: QLT091001; Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois • Baltimore, Maryland

Conditions: End Stage Renal Disease
Interventions: GHRP-1/AG 70 mg depot in ESRD, Placebo; Drug · Other
Lead sponsor: QLT Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: New Orleans, Louisiana • Rochester, Minnesota

Conditions: LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Interventions: QLT091001; Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Latanoprost; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System, Xalatan; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Choroidal Neovascularization, Macular Degeneration
Interventions: verteporfin, ranibizumab, dexamethasone; Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 21
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Prostatic Hyperplasia
Interventions: Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system; Drug · Device
Lead sponsor: QLT Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more

Conditions: Age-Related Macular Degeneration
Interventions: Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF); Drug · Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 11
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more

Conditions: Age-Related Macular Degeneration
Interventions: reduced fluence photodynamic therapy with Visudyne, Lucentis; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Neoplasms
Interventions: Chemotherapy; Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 4
States / cities: Jacksonville, Florida • Vincennes, Indiana • Arlington, Texas + 1 more

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab, dexamethasone and verteporfin, Ranibizumab; Drug
Lead sponsor: Bay Area Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more

Conditions: Melanoma (Skin)
Interventions: Detox-B adjuvant, verteporfin; Biological · Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 6
States / cities: Denver, Colorado • Aventura, Florida • Miami Beach, Florida + 3 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Impaired Dark Adaptation
Interventions: QLT091001, Placebo; Drug · Other
Lead sponsor: QLT Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Artesia, California • Santa Barbara, California • Boston, Massachusetts + 4 more

Conditions: Benign Prostatic Hyperplasia
Interventions: QLT0074, Photodynamic therapy; Drug
Lead sponsor: QLT Inc.; Industry
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • New Port Richey, Florida + 2 more

Conditions: Age-Related Macular Degeneration
Interventions: Visudyne, Kenalog; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 50 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP)
Interventions: No treatment: retrospective chart review; Other
Lead sponsor: QLT Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Portland, Oregon

Conditions: Macular Degeneration
Interventions: Verteporfin Therapy/ Drug: Bevacizumab; Device
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD